TABLE 4.
Medications after HTX – stratified by HbA1c at HTX.
| Parameter | T2DM (n = 121) | HbA1c < 7.0% (n = 67) | HbA1c ≥ 7.0% (n = 54) | Difference | 95% CI | P-value |
| Immunosuppressive drug therapy | ||||||
| Cyclosporine A, n (%) | 36 (29.8%) | 17 (25.4%) | 19 (35.2%) | 9.8% | –6.6 – 26.2% | 0.241 |
| Tacrolimus, n (%) | 85 (70.2%) | 50 (74.6%) | 35 (64.8%) | 9.8% | –6.6 – 26.2% | 0.241 |
| Azathioprine, n (%) | 16 (13.2%) | 9 (13.4%) | 7 (13.0%) | 0.4% | –11.7 – 12.5% | 0.940 |
| Mycophenolate mofetil, n (%) | 105 (86.8%) | 58 (86.6%) | 47 (87.0%) | 0.4% | –11.7 – 12.5% | 0.940 |
| Steroids, n (%) | 121 (100.0%) | 67 (100.0%) | 54 (100.0%) | 0.0% | n. a. | n. a. |
| Concomitant medications | ||||||
| ASA, n (%) | 14 (11.6%) | 9 (13.4%) | 5 (9.3%) | 4.1% | –7.1 – 15.3% | 0.476 |
| Beta blocker, n (%) | 25 (20.7%) | 18 (26.9%) | 7 (13.0%) | 13.9% | –0.1 – 27.9% | 0.060 |
| Ivabradine, n (%) | 14 (11.6%) | 9 (13.4%) | 5 (9.3%) | 4.1% | –7.1 – 15.3% | 0.476 |
| Calcium channel blocker, n (%) | 42 (34.7%) | 21 (31.3%) | 21 (38.9%) | 7.6% | –9.5 – 24.7% | 0.386 |
| ACE inhibitor/ARB, n (%) | 52 (43.0%) | 27 (40.3%) | 25 (46.3%) | 6.0% | –11.7 – 23.7% | 0.508 |
| Diuretic, n (%) | 121 (100.0%) | 67 (100.0%) | 54 (100.0%) | 0.0% | n. a. | n. a. |
| Statin, n (%) | 73 (60.3%) | 44 (65.7%) | 29 (53.7%) | 12.0% | –5.5 – 29.5% | 0.181 |
| Gastric protection †, n (%) | 121 (100.0%) | 67 (100.0%) | 54 (100.0%) | 0.0% | n. a. | n. a. |
ACE inhibitor, angiotensin-converting-enzyme inhibitor; ARB, angiotensin II receptor blocker; ASA, acetylsalicylic acid; CI, confidence interval; HbA1c, hemoglobin A1c; HTX, heart transplantation; n, number; n. a., not applicable; T2DM, type 2 diabetes mellitus; †, gastric protection defined as proton pump inhibitor (PPI) or histamine receptor (H2) blocker.